Baird Reiterates an 'Outperform' on Onyx Pharmaceuticals (ONXX); FDA approval of Kyprolis and Increased Takeover Chatter

July 23, 2012 10:25 AM EDT Send to a Friend
Get Alerts ONXX Hot Sheet
Price: $124.70 --0%

Rating Summary:
    11 Buy, 12 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 12 | Down: 7 | New: 28
Trade ONXX Now!
Join SI Premium – FREE
Baird reiterates an 'Outperform' on Onyx Pharmaceuticals (NASDAQ: ONXX), new price target of $80.00.

Late last Friday, analyst, Christopher Raymond, said, he remains a buyer following the earlier-than-expected FDA approval of Kyprolis in relapsed/refractory multiple myeloma. His checks indicated strong pent up Kyprolis demand, and thinks the stock can work higher near-term as this launch unfolds. Combining this with what he believes will be increased takeout chatter in light of the approval and the positive Nexavar competitive update, we like ONXX shares into the $80-range."

For an analyst ratings summary and ratings history on Onyx Pharmaceuticals click here. For more ratings news on Onyx Pharmaceuticals click here.

Shares of Onyx Pharmaceuticals closed at $76.38 yesterday.




You May Also Be Interested In


Related Categories

Analyst Comments, Analyst PT Change, FDA, Rumors

Related Entities

Robert W Baird

Add Your Comment